Clinical Relevance of Circulating Cell-Free Micrornas in Cancer

1

Table S1Diagnostic and prognostic value of circulating miRs in patients with different cancer entities

Cancer type / Number of patients / microRNAs / Diagnosis / Prognosis / Source / Time Point / Tumour Stages / Ref.
Lung cancer / 400 / miR-20a, miR-24, miR-25, miR-145, miR-152, miR-199-5p, miR-221, miR-222, miR-223, miR-320, / X / Serum / Pre-operative / I-IV / 1
260 / miR-125b / X / X / Serum / Inoperable / III-IV / 2
243 / miR-486, miR-30d, miR-1, miR-499 / X / Serum / after therapy / I-IIIa / 3
193 / miR-125b / X / Serum / Pre-operative / I-IV / 4
191 / miR-16 / X / Serum / Pre-operative / III-IV / 5
184 / miR-93, miR-100, miR-134, miR-151, miR-345 / X / Pleural effusion / Pre-operative / I-IV / 6
152 / miR-25, miR-223 / X / Serum / Pre-operative / - / 7
114 / miR-142-3p, miR-29b / X / Serum / Pre-operative / I-IIIa / 8
97 / miR-361-3p, miR-625 / X / Serum / Pre-/Post-operative / I-IV / 9
78 / let-7f, miR-30e-3p / X / X / Plasma vesicles / Pre-operative / - / 10
76 / miR-21, miR-210, miR-486-5p / X / Plasma / Pre-operative / I-IV / 11
74 / miR-155, miR-197, miR-182 / X / Plasma / Pre-Post-operative / I-IV / 12
70 / miR-21 / X / X / Serum / Pre-operative / I-IV / 13
65 / miR-21, miR-155, miR-182, miR-197 / X / Serum / Pre-operative / - / 14
63 / miR-21 / X / Plasma / Pre-operative / I-IV / 15
58 / miR-21, miR-126, miR-210, miR-486-5p / X / Plasma / Pre-operative / I / 16
55 / miR-15b, miR-27b / X / Serum / Pre-operative / I-IV / 17
52 / miR-20a-5p, miR-152-3p, miR-199a-5p / X / Plasma / Pre-operative / I-IIIa / 18
Breast cancer / 193 / miR-200b / X / Plasma / Metastases / - / 19
170 / miR-145, miR-451 / X / Plasma / Pre-/Post-operative / I-IV / 20
152 / miR-17, miR-34a, miR-155, miR-373 / X / Serum / Post-operative / I-IV / 21
148 / miR-10b, miR-21, miR-145, miR-155, miR-195, miR-16,let-7a / X / Plasma/Serum / Pre-/Post-operative / I-IV / 22
132 / miR-1, miR-92a, miR-133a, miR-133b / X / Serum / Pre-operative / I-IV / 23
127 / miR-148b, miR-409-3p, miR-801 / X / Plasma / Pre-operative / I-IV / 24
103 / miR-155 / X / Serum / Pre-/Post-operative / I-III / 25
102 / miR-20a, miR-21, miR-214 / X / Serum / Pre-/Post-operative / I-IV / 26
102 / miR-21 / X / X / Serum / Pre-operative / I-IV / 27
100 / miR-92a, miR-21 / X / Serum / Pre-operative / I-III / 28
89 / miR-10b, miR-34a, miR-141, miR-155 / X / Serum / Post-operative / I-IV / 29
75 / miR-215, miR-299-5P, miR-411, miR-452 / X / Serum / Pre-operative / I-IV / 30
68 / miRNA-21, miR-106a, miR-126, miR-155, miR-199a, miR-335 / X / Serum / Pre-operative / I-IIIa / 31
61 / miR-10b, miR-21, miR-125b, miR-145, miR-155 miR-191, miR-382 / X / Serum / Pre-operative / I-III / 32
60 / miR-10b, miR-373 / X / Plasma / Pre-operative / I-IV / 33
Ovarian cancer / 96 / miR-221 / X / X / Serum / Pre-operative / I-IV / 34
94 / miR-21 / X / Serum / Pre-operative / I-IV / 35
Cervical cancer / 90 / miR-218 / X / Serum / Pre-operative / I-IV / 36
80 / miR-1246, miR-20a, miR-2392, miR-3147, miR-3162-5p,miR-4484 / X / Serum / Pre-operative / Ib-IIa / 37
80 / miR-20a, miR-203 / X / Serum / Pre-operative / I-IIa / 38
Prostate cancer / 84 / miR-375, miR-141, miR-378*, miR-409-3p / X / Serum / Pre-operative / 1-3 / 39
82 / miR-20a, miR-21, miR-145, miR-221 / X / Plasma / Pre-operative / 2a-4 / 40
80 / let-7e, let-7c, miR-30c, miR-622, miR-1285 / X / Plasma / Pre-operative / - / 41
78 / miR-107, miR-574-3p, miR-141, miR-375, miR-200b / X / Various body fluids / Pre-/Post-operative / 1-4 / 42
71 / miR-375, miR-141 / X / Serum / Pre-operative / - / 43
70 / miR-141, miR-146b-3p, miR-194 / X / Serum / Pre-operative / 2-4 / 44
51 / miR-21, miR-141, miR-221 / X / Plasma / Pre-operative / - / 45
50 / miR-141, miR375, miR-200c, miR151-3p, miR423-3p, miR-126, miR152, miR-21, miR-16, miR-205 / X / Plasma / Pre-operative / 1c-3 / 46
50 / miR-21 / X / Serum / Pre-operative / - / 47
Renal cell cancer / 90 / miR-378, miR-451 / X / Serum / Pre-operative / 1-4 / 48
84 / miR-1233 / X / Serum / Pre-operative / 1-4 / 49
68 / miR-210 / X / Serum / Pre-/Post-operative / I-III / 50
Colorectal cancer / 161 / miR-409-3p, miR-7, miR-93 / X / Plasma / Pre-operative / A-D / 51
157 / miR-29a, miR-92a / X / Plasma / Pre-operative / 1-4 / 52
123 / miR18a, miR19a, miR19b, miR15b, miR29a, miR335 / X / Plasma / Pre-operative / I-IV / 53
102 / miR-141 / X / X / Plasma / Pre-operative / I-IV / 54
90 / miR-601, miR-760 / X / Plasma / Pre-operative / I-IV / 55
90 / miR-17-3p, miR-92 / X / Plasma / Pre-/Post-operative / I-IV / 56
70 / miR-193a-3p, miR-23a, miR-338-5p / X / Blood / Pre-operative / I-IV / 57
63 / miR-34a / X / Blood / Pre-operative / I-IV / 58
61 / miRNA-29c / X / Serum / Pre-operative / II/III / 59
50 / miR-18a, miR-20a, miR-21, miR-29a, miR-92a, miR-106b, miR-133a, miR-143, miR-145 / X / Plasma / Pre-operative / I-IV / 60
Gastric cancer / 164 / miR-1, miR-20a, miR-27a, miR-34, miR-423-5p / X / Serum / Pre-operative / I-IV / 61
90 / miR-106a, miR-17 / X / Blood / Pre-/Post-operative / - / 62
76 / miR-196a / X / X / Serum / Pre-operative / - / 63
71 / miR-17-5p, miR-20a / X / X / Plasma / Pre-/Post-operative / I-IV / 64
69 / miR-17-5p, miR-21, miR-106a, miR-106b, let-7a / X / Plasma / Pre-/Post-operative / I-IV / 65
69 / miR-21 / X / Plasma / Pre-operative / I-IV / 66
67 / miR-200c / X / X / Blood / Pre-operative / I-IV / 67
61 / miR-187, miR-371-5p, miR-378 / X / Serum / Pre-operative / I-IV / 68
60 / 106b, miR-20a, miR-221 / X / Plasma / Pre-operative / I-IV / 69
60 / miR-223, miR-21, miR-218 / X / Plasma / Pre-operative / I-IV / 70
58 / miR-221, miR-376c, miR-744 / X / Serum / Pre-operative / - / 71
50 / miR-199a-3p / X / Plasma / Pre-/Post-operative / Ia-IIa / 72
Hepatocellular cancer / 390 / miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, miR-801 / X / Plasma / Pre-operative / A-D / 73
195 / miR-1, miR-122 / X / Serum / Pre-operative / A-D / 74
126 / miR-21 / X / Plasma / Pre-/Post-operative / I-IIIa / 75
120 / miR-25, miR-375, let-7f / X / Serum / Pre-operative / I-III / 76
105 / miR-16, miR-199a / X / Serum / Pre-operative / - / 77
86 / miR-18a / X / Serum / Pre-operative / I-IV / 78
57 / miR-15b, miR-130b / X / Serum / Pre-/Post-operative / I-IV / 79
Pancreatic cancer / 197 / miR-21 / X / Serum / Pre-operative / I-IV / 80
140 / miR-16, miR-21, miR-155, miR-181a, miR-181b, miR-196a, miR-210 / X / Plasma / Pre-operative / I-IV / 81
Oesophageal cancer / 290 / miR-10a, miR-22, miR-100, miR-148b, miR-223, miR-133a, miR-127-3p / X / Serum / Pre-operative / I-IV / 82
106 / miR-18a / X / Plasma / Pre-operative / I-IV / 83
101 / miR-1246 / X / X / Serum / Pre-operative / I-IV / 84
71 / miR-21 / X / Serum / Pre-treatment / I-IV / 85
64 / miR-21, miR-145, miR-200c, let-7c / X / Serum / Pre-treatment / I-IV / 86
60 / miR-155, miR-183 / X / Plasma / Pre-treatment / - / 87
50 / miR-21, miR-375 / X / Plasma / Pre-Post-operative / I-IV / 88
Head and neck cancer / 50 / miR-21 / X / Plasma / Pre-/Post-operative / I-IV / 89
Thyroid cancer / 106 / let-7e, miR-151-5p, miR-222 / X / Serum / Pre-operative / I-IV / 90
Brain Tumours / 122 / miR-15b*, miR-23a, miR-133a, miR-150*, miR-197, miR-497, miR-548b-5p / X / Serum / Pre-operative / III-IV / 91
Melanoma / 94 / miR-221 / X / X / Serum / Pre-/Post-operative / II-IV / 92
80 / miR-150, miR-15b, miR-199a-5p, miR-33a, miR-424 / X / Serum / Pre-/Post-operative / I-III / 93
Myelodysplasia / 50 / let-7a, miR-16 / X / Plasma / - / 1-2 / 94
Lymphoma / 79 / miR-221 / X / X / Plasma / - / I-IV / 95
75 / miR-15a, miR-16-1, miR-29c, miR-155, miR-34a / X / Serum / - / I-IV / 96
60 / miR-21 / X / X / Serum / - / I-IV / 97
Leukaemia / 228 / miR-155 / X / Plasma/Vesicles / - / I-IV / 98
140 / miR-10a-5p, miR-93-5p, miR-129-5p, miR-155-5p, miR-181b-5p, miR-320d / X / Serum / - / M1-M5 / 99
77 / miR-92a, miR-638 / X / Plasma / - / M1-M7 / 100

This table is not comprehensive and is based on our review of studies with more than 50 patients. The quantification of circulating microRNAs was carried out by quantitative real-time PCR.

1.Chen, X. et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer130, 1620-8 (2012).

2.Cui, E.H. et al. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol Sin34, 309-13 (2013).

3.Hu, Z. et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol28, 1721-6 (2010).

4.Yuxia, M., Zhennan, T. & Wei, Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol138, 2045-50 (2012).

5.Wang, Y. et al. Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non-Small Cell Lung Cancer. Cancer Res73, 4801-9 (2013).

6.Wang, T. et al. Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS One7, e43268 (2012).

7.Chen, X. et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res18, 997-1006 (2008).

8.Kaduthanam, S. et al. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer80, 223-7 (2013).

9.Roth, C. et al. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS One7, e38248 (2012).

10.Silva, J. et al. Vesicle-related microRNAs in plasma of NSCLC patients and correlation with survival. Eur Respir J37, 617-23 (2011).

11.Shen, J. et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer11, 374 (2011).

12.Zheng, D. et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol4, 575-86 (2011).

13.Liu, X.G. et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol29, 618-26 (2012).

14.Abd-El-Fattah, A.A., Sadik, N.A., Shaker, O.G. & Aboulftouh, M.L. Differential MicroRNAs Expression in Serum of Patients with Lung Cancer, Pulmonary Tuberculosis, and Pneumonia. Cell Biochem Biophys67, 875-84 (2013).

15.Wei, J. et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer30, 407-14 (2011).

16.Shen, J. et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest91, 579-87 (2011).

17.Hennessey, P.T. et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One7, e32307 (2012).

18.Sanfiorenzo, C. et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One8, e54596 (2013).

19.Madhavan, D. et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res18, 5972-82 (2012).

20.Ng, E.K. et al. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One8, e53141 (2013).

21.Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K. & Schwarzenbach, H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem59, 1489-96 (2013).

22.Heneghan, H.M. et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg251, 499-505 (2010).

23.Chan, M. et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res19, 4477-87 (2013).

24.Cuk, K. et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer132, 1602-12 (2013).

25.Sun, Y. et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One7, e47003 (2012).

26.Schwarzenbach, H., Milde-Langosch, K., Steinbach, B., Muller, V. & Pantel, K. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat134, 933-41 (2012).

27.Asaga, S. et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem57, 84-91 (2011).

28.Si, H. et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol139, 223-9 (2013).

29.Roth, C. et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res12, R90 (2010).

30.van Schooneveld, E. et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res14, R34 (2012).

31.Wang, F., Zheng, Z., Guo, J. & Ding, X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol119, 586-93 (2010).

32.Mar-Aguilar, F. et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers34, 163-9 (2013).

33.Chen, W., Cai, F., Zhang, B., Barekati, Z. & Zhong, X.Y. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol34, 455-62 (2013).

34.Hong, F., Li, Y., Xu, Y. & Zhu, L. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J Int Med Res41, 64-71 (2013).

35.Xu, Y.Z., Xi, Q.H., Ge, W.L. & Zhang, X.Q. Identification of Serum MicroRNA-21 as a Biomarker for Early Detection and Prognosis in Human Epithelial Ovarian Cancer. Asian Pac J Cancer Prev14, 1057-60 (2013).

36.Yu, J. et al. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol138, 671-4 (2012).

37.Chen, J. et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med32, 557-67 (2013).

38.Zhao, S., Yao, D., Chen, J. & Ding, N. Circulating miRNA-20a and miRNA-203 for Screening Lymph Node Metastasis in Early Stage Cervical Cancer. Genet Test Mol Biomarkers17, 631-6 (2013).

39.Nguyen, H.C. et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate73, 346-54 (2013).

40.Shen, J. et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate72, 1469-77 (2012).

41.Chen, Z.H. et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate72, 1443-52 (2012).

42.Bryant, R.J. et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer106, 768-74 (2012).

43.Brase, J.C. et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer128, 608-16 (2011).

44.Selth, L.A. et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer109, 641-50 (2013).

45.Yaman Agaoglu, F. et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol32, 583-8 (2011).

46.Watahiki, A. et al. Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer. Int J Mol Sci14, 7757-70 (2013).

47.Zhang, H.L. et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate71, 326-31 (2011).

48.Redova, M. et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med10, 55 (2012).

49.Wulfken, L.M. et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One6, e25787 (2011).

50.Zhao, A., Li, G., Peoc'h, M., Genin, C. & Gigante, M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol94, 115-20 (2013).

51.Wang, S. et al. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer (2013).

52.Huang, Z. et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer127, 118-26 (2010).

53.Giraldez, M.D. et al. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol11, 681-8 e3 (2013).

54.Cheng, H. et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One6, e17745 (2011).

55.Wang, Q. et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One7, e44398 (2012).

56.Ng, E.K. et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut58, 1375-81 (2009).

57.Yong, F.L., Law, C.W. & Wang, C.W. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer13, 280 (2013).

58.Nugent, M., Miller, N. & Kerin, M.J. Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol106, 947-52 (2012).

59.Yang, I.P. et al. The Functional Significance of MicroRNA-29c in Patients with Colorectal Cancer: A Potential Circulating Biomarker for Predicting Early Relapse. PLoS One8, e66842 (2013).

60.Luo, X., Stock, C., Burwinkel, B. & Brenner, H. Identification and evaluation of plasma MicroRNAs for early detection of colorectal cancer. PLoS One8, e62880 (2013).

61.Liu, R. et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer47, 784-91 (2011).

62.Zhou, H. et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med (Berl)88, 709-17 (2010).

63.Tsai, K.W. et al. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer51, 394-401 (2012).

64.Wang, M. et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Rep5, 1514-20 (2012).

65.Tsujiura, M. et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer102, 1174-9 (2010).

66.Komatsu, S. et al. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res33, 271-6 (2013).

67.Valladares-Ayerbes, M. et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med10, 186 (2012).

68.Liu, H. et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett316, 196-203 (2012).

69.Cai, H. et al. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol30, 452 (2013).

70.Li, B.S. et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One7, e41629 (2012).

71.Song, M.Y. et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One7, e33608 (2012).

72.Li, C. et al. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol108, 89-92 (2013).

73.Zhou, J. et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol29, 4781-8 (2011).

74.Koberle, V. et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer49, 3442-9 (2013).

75.Tomimaru, Y. et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol56, 167-75 (2012).

76.Li, L.M. et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res70, 9798-807 (2010).

77.Qu, K.Z., Zhang, K., Li, H., Afdhal, N.H. & Albitar, M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol45, 355-60 (2011).

78.Li, L., Guo, Z., Wang, J., Mao, Y. & Gao, Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci57, 2910-6 (2012).

79.Liu, A.M. et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open2, e000825 (2012).

80.Liu, R. et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem58, 610-8 (2012).

81.Liu, J. et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer131, 683-91 (2012).

82.Zhang, C. et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem56, 1871-9 (2010).

83.Hirajima, S. et al. Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer108, 1822-9 (2013).

84.Takeshita, N. et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer108, 644-52 (2013).

85.Kurashige, J. et al. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol106, 188-92 (2012).

86.Tanaka, K. et al. Circulating miR-200c Levels Significantly Predict Response to Chemotherapy and Prognosis of Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Cancer. Ann Surg Oncol20 Suppl 3, 607-15 (2013).

87.Liu, R. et al. Circulating miR-155 expression in plasma: a potential biomarker for early diagnosis of esophageal cancer in humans. J Toxicol Environ Health A75, 1154-62 (2012).

88.Komatsu, S. et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer105, 104-11 (2011).

89.Hsu, C.M. et al. Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. Tumour Biol33, 1933-42 (2012).

90.Yu, S. et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab97, 2084-92 (2012).

91.Yang, C. et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer132, 116-27 (2013).

92.Kanemaru, H. et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci61, 187-93 (2011).

93.Friedman, E.B. et al. Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med10, 155 (2012).

94.Zuo, Z. et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood118, 413-5 (2011).

95.Guo, H.Q., Huang, G.L., Guo, C.C., Pu, X.X. & Lin, T.Y. Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma. Dis Markers29, 251-8 (2010).

96.Fang, C. et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol91, 553-9 (2012).

97.Lawrie, C.H. et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol141, 672-5 (2008).

98.Ferrajoli, A. et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood122, 1891-9 (2013).

99.Zhi, F. et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS One8, e56718 (2013).

100.Tanaka, M. et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One4, e5532 (2009).

1